Query
Disregulation of cellular differentiation trying to repair endothelium repair from persistent spike expression from insertional mutagenesis
**This describes a hypothesized pathological cascade linking SARS-CoV-2 (or vaccine-induced) spike protein expression to impaired vascular repair and formation of persistent, amyloid-like fibrinogen aggregates (sometimes called "fibrinaloids" or amyloid-fibrinogen microclots) with prion-like properties.**
### Endothelial Damage and Disrupted Repair by Spike Protein
The **spike protein** (S1 subunit especially) directly damages endothelial cells (ECs), the lining of blood vessels, even without full viral infection. It binds ACE2, integrins (e.g., α5ÎČ1 via its RGD motif), and other receptors, triggering:
- Downregulation of ACE2 â mitochondrial dysfunction, oxidative stress, and reduced nitric oxide (eNOS impairment).
- Activation of NF-ÎșB, pro-inflammatory cytokines, and calcium dysregulation (e.g., via TRPV4).
- Degradation or redistribution of junctional proteins (VE-cadherin, PECAM-1, JAMs, connexins) â increased permeability, leakage, and thrombosis risk.
This creates ongoing endothelial injury. Normal repair involves EC proliferation, migration, and proper differentiation to restore the monolayer and recruit pericytes/smooth muscle for vessel stability. Spike disrupts this homeostasis, promoting sustained inflammation and barrier failure.
**Endothelial-to-mesenchymal transition (EndMT)** is relevant here. Spike-related peptides (including from S and M proteins) can induce EndMT in microvascular ECs from various tissues (lungs, heart, etc.) via TGF-ÎČ signaling. In EndMT, ECs lose endothelial markers and gain mesenchymal/fibroblast-like traits, contributing to fibrosis, impaired angiogenesis, and failed vessel repair rather than normal regeneration. This transdifferentiation diverts cells away from proper endothelial differentiation.
*Illustration of normal vs. activated/dysfunctional endothelium: tight junctions, pericyte interactions, and shifts to pro-thrombotic/inflammatory states with fibrin, leukocyte adhesion, etc.*
### Link to Amyloid Fibrinogen Aggregates ("Novel Amyloid Fibrinogen Prions")
Spike protein has multiple **amyloidogenic sequences** (e.g., residues ~192-211, 601-620, 685-701, 1166-1185). These can form fibrils, especially after cleavage by neutrophil elastase (abundant in inflammation). Key effects on fibrinogen:
- Spike binds directly to fibrinogen chains (BÎČ and Îł especially), inducing conformational change: α-helices â ÎČ-sheets â amyloid-like misfolding.
- This promotes dense, thrombin-independent microclots (fibrinaloids) that incorporate fibrin(ogen), spike fragments, and inflammatory molecules (e.g., α2-antiplasmin).
- These aggregates resist plasmin-mediated fibrinolysis â persistent microclots that obstruct capillaries, cause hypoxia, and drive chronic inflammation.
In vitro, adding spike (or its amyloid fibrils) to normal plasma or fibrinogen reproduces these resistant structures seen in COVID-19/Long COVID patients. Spike685 fibrils, for example, create dense networks and incorporate fibrin into lysis-resistant forms.
**Prion-like aspects**: Amyloids are self-propagating via seeding. Spike amyloid fibrils can accelerate fibril formation in human prion protein (PrP), amyloid-ÎČ, and other proteins. Fibrinogen amyloids behave similarlyâonce seeded, they can propagate misfolding, trap more proteins, and persist. This fits "novel amyloid fibrinogen prions" as stable, transmissible (in a proteopathic sense) aggregates contributing to ongoing pathology.
### Overall Mechanism and Implications
1. Spike expression (infection or mRNA) â endothelial injury inflammation.
2. Disrupted repair/differentiation (e.g., EndMT instead of proper EC regeneration) â chronic vascular dysfunction.
3. Direct spike-fibrinogen interaction amyloid seeding â persistent, fibrinolysis-resistant microclots.
4. Feedback loop: Microclots worsen hypoxia/inflammation â more damage and seeding.
This aligns with observations in Long COVID, some post-vaccination cases, and related coagulopathies. Symptoms like fatigue, brain fog, POTS, and organ issues can stem from microvascular occlusion and impaired perfusion. Not everyone is equally affected (genetics, dose, inflammation level play roles), and some studies show variable binding/impact in solution vs. surface-bound contexts.
Research in this area is active and evolving, with debates on exact prevalence and causality. Therapies targeting fibrinolysis enhancement, anti-amyloid approaches, or endothelial protection are under discussion. Consult peer-reviewed sources and medical professionals for individual cases.